Mona Ashiya - 27 Jul 2026 Form 4 Insider Report for Yarrow Bioscience, Inc. (VYNE)

Reporting relationship: Director
Issuer ticker: VYNE
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 21:36:56 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Zeronda, as attorney-in-fact for Mona Ashiya

Key filing fact

Mona Ashiya filed Form 4 for Yarrow Bioscience, Inc. (VYNE) on 29 Jul 2026.

Key facts

This page summarizes Mona Ashiya's Form 4 filing for Yarrow Bioscience, Inc. (VYNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2026, 21:36.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794070 Primary reporting owner

Ashiya Mona

Relationship: Director
Address: C/O YARROW BIOSCIENCE, INC., 470 JAMES STREET, SUITE 007, NEW HAVEN
Signature: /s/ Tyler Zeronda, as attorney-in-fact for Mona Ashiya
Signature date: 29 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +15,435
Change %
Price: $0.000000^*
Shares after: 15,435
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,435
Exercise price: $28.56
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents a right to purchase 15,435 shares of the Issuer's common stock, which vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments X, LP.